MX2013005699A - Composiciones de interferon-beta estables conservadas. - Google Patents

Composiciones de interferon-beta estables conservadas.

Info

Publication number
MX2013005699A
MX2013005699A MX2013005699A MX2013005699A MX2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A MX 2013005699 A MX2013005699 A MX 2013005699A
Authority
MX
Mexico
Prior art keywords
interferon
beta
preserved compositions
stable preserved
stable
Prior art date
Application number
MX2013005699A
Other languages
English (en)
Spanish (es)
Inventor
Mark Brader
Anisa Vaidya
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MX2013005699A publication Critical patent/MX2013005699A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2013005699A 2010-11-22 2011-11-22 Composiciones de interferon-beta estables conservadas. MX2013005699A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41629110P 2010-11-22 2010-11-22
PCT/US2011/061759 WO2012071366A1 (en) 2010-11-22 2011-11-22 Stable preserved compositions if interferon-beta

Publications (1)

Publication Number Publication Date
MX2013005699A true MX2013005699A (es) 2013-08-27

Family

ID=46146183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005699A MX2013005699A (es) 2010-11-22 2011-11-22 Composiciones de interferon-beta estables conservadas.

Country Status (7)

Country Link
US (1) US20120269770A1 (cg-RX-API-DMAC7.html)
EP (1) EP2643469A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013543872A (cg-RX-API-DMAC7.html)
AU (1) AU2011331992A1 (cg-RX-API-DMAC7.html)
CA (1) CA2818671A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013005699A (cg-RX-API-DMAC7.html)
WO (1) WO2012071366A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130811A1 (en) * 2013-02-22 2014-08-28 Biogen Idec Ma Inc Interferon beta formulation
WO2016163764A2 (ko) * 2015-04-07 2016-10-13 에이비온 주식회사 인터페론 베타 변이체의 안정화 제제
FI126979B (en) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
RS52417B (sr) * 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta

Also Published As

Publication number Publication date
US20120269770A1 (en) 2012-10-25
CA2818671A1 (en) 2012-05-31
WO2012071366A8 (en) 2013-06-20
AU2011331992A1 (en) 2013-06-13
JP2013543872A (ja) 2013-12-09
EP2643469A1 (en) 2013-10-02
WO2012071366A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
IN2012DN00746A (cg-RX-API-DMAC7.html)
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
AU333422S (en) Showerhead
MY181898A (en) Heterocyclic compounds and uses thereof
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
PH12013500386A1 (en) Pesticidal compositions
PH12013500500A1 (en) Fused heteroaryls and their uses
PH12013500241A1 (en) Modified relaxin polypeptides and their uses
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
PH12013500885B1 (en) Pesticidal compositions and processes related thereto
MX2013004981A (es) Composiciones y metodos para la administracion de agentes terapeuticos.
IN2014DN03298A (cg-RX-API-DMAC7.html)
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MY161601A (en) Films and compositions comprising the same
PH12013501311A1 (en) Polymer systems
IN2012DN03404A (cg-RX-API-DMAC7.html)
IN2014DN02926A (cg-RX-API-DMAC7.html)
WO2011130697A3 (en) Tissue targeting
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
MX2013006525A (es) Composiciones farmaceuticas que comprenden alisporivir.
MX344189B (es) Formulaciones de mazindol.
WO2012071366A8 (en) Stable preserved compositions of interferon-beta
PH12012501547A1 (en) Methods of preparing thiazolidines
UA61166U (en) Use of glucosamine hydrochloride as antiamnestic and antihypoxic agent
UA41660U (en) Use of jacton and mexidol as actoprotector

Legal Events

Date Code Title Description
FA Abandonment or withdrawal